Beware of underwater holders ramping on these boards. They want you to buy so they can sell. |
You could try the financial reports - just a guess :-/ |
We seek him everywhere |
Beware of STT all members |
Given the supposedly good rns yesterday, there's a distinct lack of posts from the usual rampers.
They have obviously sold up and moved on. No more hundreds of trades to move the share price Coincidence???
The newsflow here has been as expected.
The chairman dumping his entire holding whilst company being talked up.
The CEO's huge options.
etc
etc |
No debt..
After the recent acquisition they have £34 million in cash |
Does this company have net debt?? Am intrigued by this and tempted to stick my toe in... |
Shionogi published positive results from a human challenge trial, conducted by #HVO, for its RSV antiviral candidate. These results demonstrate the significant role that human challenge trials can play in the drug development space, by generating rapid efficacy data and reducing risk in later-stage trials. This is important for viruses such as RSV, that severely impacts vulnerable patients such as infants, the elderly and immunocompromised individuals.With hVIVO's decades of expertise in human challenge trials, the team can leverage this knowledge to accelerate the delivery of promising new treatments to patients. Shionogi, a leading global research-driven pharmaceutical company headquartered in Osaka, Japan, also released their own press release on the positive news here : |
Please could someone advise the link for the telegram group. Thankyou. |
chica
"if Mo had gotten these contracts over the line in the 4th quarter Hvivo would be over 30p now."
Why? The chairman dumped his entire holding at 28p/29p, the latest only last July. He's set a ceiling until the company can announce some clarity.
I think investors are waiting for the results. |
Is the latest thing not to give out any useable numbers ? So thats the trading update and the contracts with nowt in them. |
Do you really believe that? |
Bought some more today.
Timing is everything..if Mo had gotten these contracts over the line in the 4th quarter Hvivo would be over 30p now. |
Disappointing price action here. |
Price rejecting 8 day and 50 day moving average. Hmmmm. |
Oh look another contract. |
 Yet another Company to add to their lists of contacts for HVO Https://www.londonstockexchange.com/news-article/HVO/rsv-contract-signed-with-inhalon-biopharma/16880482hVIVO is delighted to add yet another company to its list of clients - Inhalon Biopharma.The Company has signed a human challenge trial contract which will assess Inhalon's inhaled (mucosal) IN-002 antiviral candidate using hVIVO's world renowned RSV Human Challenge Model. The study will take place at their state-of-the-art facility in Canary Wharf in H2 2026, with the majority of revenue expected to be recognised in 2026.hVIVO previously identified the next generation of vaccines and antivirals to include mucosal based delivery systems and had targeted this as a being a key growth drive for their challenge trial business going forward.They are delighted to have received such an exciting project, particularly with a new client. The company has now seen a number of contracts coming across the line recently and the orderbook for 2026 growing with this latest contract. |
That's the way. Sounds like you have a plan. Most don't. Good luck. |
No, the next time it gets back to late 20's the market will have realised the potential. It will be backed by new contract announcements (possibly phase 111) and show the obvious benefits of new facilities and synergy with the new acquisitions. Picked up lots of these when the idiots were talking it down at 10p and 12p. Current price is a similar buying opportunity. Ignore the morons and use your brains for good gains over next 9-18months. |
Nobody thought of that at 30p, ii’s buying was a sure sign of future success, although timescale wasn’t forthcoming |
adorling,
"Institutions don’t increase their stake from 5% to nearly 13% without having a deeper insight into the future growth and strategy of the Company."
The assertion works both ways
What about those IIs, like JPM, who are dumping their holding?
Have they dumped their stake with that a 'deeper insight into future growth'?
What do they see? Is it the same as the chairman? |
JPM out..
If memory serves me right they bought early 20p's.
Did they also buy north of 28p?
She was very bullish sad to see them gone |
Inaminute,
"That is why it makes me laugh when the halfwits on here disparage the company. "
Facts:
The chairman dumped his entire holding in 2 stages, majority a year ago, Feb then the remaining last July 4 working days after the TU, selling at 28p/29p.
The chairman dumped his holding whilst the company was being talked up and while IIs buying/increasing.
The CEO's huge options start to exercise in few days.
I believe the chairman knows more about the company than any II/PI.
I believe the chairman dumping his holding is a red flag.
Do you agree?
I believe awarding huge options to 1 snr exec gives an incentive to talk the company up.
My post below was before the chairman dumped the remaining entire holding, 4 working days later:
The newsflow has been as predicted.
sikhthetech - 17 Jul 2024 - 12:18:23 - 7592 of 9307 hVIVO plc - HVO
Adorling
"Having just attended an insightful 2 hours at the hVIVO Capital Markets Day presentations I feel very reassured by the excellent and professional Management Team lead by CEO Mo Khan"
As predicted.
The CEO's huge options were awarded last year and backdated by a year.
Do you think it's a coincidence that the company is being talked up just months before those options are exercisable?
The Chairman dumped majority of his holding at a discount?
I think the Chairman knows more about the company than anyone else.
Do you?
The is a red flag.
The company newsflow shows revenue growth has slowed significantly. The lack of contracts this year and fall in contracted order book re-confirm it.
When a company is talked up, some will buy in on the hype.
The biggest red flag is 1gw and his mates lack of comments. |
Until they sell |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
